The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study Comparative Study
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear. ⋯ Edoxaban administered once daily after initial treatment with heparin was noninferior to high-quality standard therapy and caused significantly less bleeding in a broad spectrum of patients with venous thromboembolism, including those with severe pulmonary embolism. (Funded by Daiichi-Sankyo; Hokusai-VTE ClinicalTrials.gov number, NCT00986154.).
-
Letter Case Reports
Pancreatic atrophy--a new late toxic effect of sorafenib.